‌

US Patent 11359015 Humanized or chimeric CD3 antibodies

Patent 11359015 was granted and assigned to Genmab A/S on June, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

June 14, 2022

Patent Application Number

15744317

Date Filed

July 14, 2016

Patent Citations

US Patent 10590206 Inert format

US Patent 10906991 Bispecific antibodies and methods for production thereof

US Patent 10597464 Heterodimeric antibody Fc-containing proteins and methods for production thereof

US Patent 11180572 Dimeric protein with triple mutations

US Patent 10344050 Production of heterodimeric proteins

US Patent 10407501 Humanized or chimeric CD3 antibodies

US Patent 10465006 Humanized or chimeric CD3 antibodies

US Patent 10544220 Bispecific antibodies against CD3 and CD20

Patent Citations Received

US Patent 11858995 Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia

0

US Patent 11485796 Inert format

Patent Primary Examiner

CPC Code

...

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11359015 Humanized or chimeric CD3 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.